Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Neurocognitive Performance Related to Verbal Fluency as Measured by Retrieval Fluency Standard Scores

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy

What was measured

Scores measuring verbal fluency were obtained from Retrieval Fluency standard scores on the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.

Analysis population: Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group25
Intermediate-Risk Group50
High-Risk Group10

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Low-Risk Group1
Intermediate-Risk Group6
High-Risk Group0
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group117.0Not reportedNot reportedNot reportedNot reported
Intermediate-Risk Group87.718.4Not reportedNot reportedNot reported
Prior to Maintenance Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group2
Intermediate-Risk Group9
High-Risk Group0
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group97.05.7Not reportedNot reportedNot reported
Intermediate-Risk Group89.413.4Not reportedNot reportedNot reported
Completion of Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group4
Intermediate-Risk Group14
High-Risk Group0
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group90.013.2Not reportedNot reportedNot reported
Intermediate-Risk Group95.314.4Not reportedNot reportedNot reported
12 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group6
Intermediate-Risk Group21
High-Risk Group2
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group94.811.4Not reportedNot reportedNot reported
Intermediate-Risk Group86.119.9Not reportedNot reportedNot reported
High-Risk Group87.01.4Not reportedNot reportedNot reported
24 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group10
Intermediate-Risk Group26
High-Risk Group4
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group98.89.7Not reportedNot reportedNot reported
Intermediate-Risk Group82.520.6Not reportedNot reportedNot reported
High-Risk Group90.84.6Not reportedNot reportedNot reported
36 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group12
Intermediate-Risk Group27
High-Risk Group5
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group100.213.3Not reportedNot reportedNot reported
Intermediate-Risk Group88.124.9Not reportedNot reportedNot reported
High-Risk Group81.414.9Not reportedNot reportedNot reported
48 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group13
Intermediate-Risk Group25
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group77.116.0Not reportedNot reportedNot reported
Intermediate-Risk Group88.716.0Not reportedNot reportedNot reported
High-Risk Group95.715.0Not reportedNot reportedNot reported
60 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group14
Intermediate-Risk Group18
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group81.922.1Not reportedNot reportedNot reported
Intermediate-Risk Group87.916.4Not reportedNot reportedNot reported
High-Risk Group70.323.7Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        117.0
      2. group Id
        OG001
        spread
        18.4
        value
        87.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        5.7
        value
        97.0
      2. group Id
        OG001
        spread
        13.4
        value
        89.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        9
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    Prior to Maintenance Therapy
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.2
        value
        90.0
      2. group Id
        OG001
        spread
        14.4
        value
        95.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    Completion of Therapy
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.4
        value
        94.8
      2. group Id
        OG001
        spread
        19.9
        value
        86.1
      3. group Id
        OG002
        spread
        1.4
        value
        87.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        21
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    12 Months Off Therapy
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.7
        value
        98.8
      2. group Id
        OG001
        spread
        20.6
        value
        82.5
      3. group Id
        OG002
        spread
        4.6
        value
        90.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        4
      units
      Participants
    title
    24 Months Off Therapy
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.3
        value
        100.2
      2. group Id
        OG001
        spread
        24.9
        value
        88.1
      3. group Id
        OG002
        spread
        14.9
        value
        81.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        27
      3. group Id
        OG002
        value
        5
      units
      Participants
    title
    36 Months Off Therapy
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.0
        value
        77.1
      2. group Id
        OG001
        spread
        16.0
        value
        88.7
      3. group Id
        OG002
        spread
        15.0
        value
        95.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        25
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    48 Months Off Therapy
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.1
        value
        81.9
      2. group Id
        OG001
        spread
        16.4
        value
        87.9
      3. group Id
        OG002
        spread
        23.7
        value
        70.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        14
      2. group Id
        OG001
        value
        18
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    60 Months Off Therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    2. group Id
      OG001
      value
      50
    3. group Id
      OG002
      value
      10
    units
    Participants
description
Scores measuring verbal fluency were obtained from Retrieval Fluency standard scores on the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.
dispersion Type
Standard Deviation
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
MEAN
population Description
Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.
reporting Status
POSTED
time Frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy
title
Neurocognitive Performance Related to Verbal Fluency as Measured by Retrieval Fluency Standard Scores
type
SECONDARY
unit Of Measure
score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice